1. Brown, E.E.F., et al., Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction. Int J Mol Sci, 2021. 22(5).
2. Kim, J., et al., Current approaches to HIV vaccine development: a narrative review. J Int AIDS Soc, 2021. 24 Suppl 7(Suppl 7): p. e25793.
3. Gao, Q., et al., Development of an inactivated vaccine candidate for SARS-CoV-2. Science, 2020. 369(6499): p. 77-81.
4. Gu, M., et al., One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization. Emerg Microbes Infect, 2021. 10(1): p. 2016-2029.
5. Kolesov, D.E., et al., Fast and Accurate Surrogate Virus Neutralization Test Based on Antibody-Mediated Blocking of the Interaction of ACE2 and SARS-CoV-2 Spike Protein RBD. Diagnostics (Basel), 2022. 12(2).
6. Bewley, K.R., et al., Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nat Protoc, 2021. 16(6): p. 3114-3140.
7. Chang, S., et al., The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope. PLoS One, 2016. 11(3): p. e0149467.
8. Wang, Y., et al., Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. J Virol, 2021. 95(8).
9. Leander Johansen, J., et al., A new versatile and compact lentiviral vector. Mol Biotechnol, 2005. 29(1): p. 47-56.
10. Abdelmageed, A.A. and M.C. Ferran, The Propagation, Quantification, and Storage of Vesicular Stomatitis Virus. Curr Protoc Microbiol, 2020. 58(1): p. e110.